SBIR-STTR Award

Testing the effects of a selective calpain-2 inhibitor on spontaneous recurrent seizures in mouse models of epilepsy
Award last edited on: 3/6/2025

Sponsored Program
SBIR
Awarding Agency
NIH : NINDS
Total Award Amount
$706,597
Award Phase
2
Solicitation Topic Code
853
Principal Investigator
Michel Baudry

Company Information

NeurAegis Inc

5001 Alcorn Lane Suite 253
Irvine, CA 92603
   (858) 353-5749
   info@neuraegis.com
   www.neuraegis.com
Location: Single
Congr. District: 47
County: Orange

Phase I

Contract Number: 1R41NS130825-01A1
Start Date: 9/1/2023    Completed: 5/31/2025
Phase I year
2023
Phase I Amount
$489,268
Epilepsy is the most prevalent neurological diseases after migraines. Current antiepileptic drug treatmentsmainly attempt to reduce excitation or enhance inhibition in order to control seizures. Unfortunately, suchtherapeutics result in a number of undesirable side-effects, and demonstrate limited efficacy against drug-resistant cases of epilepsy. So far, no treatment has been developed as an anti-epileptogenic agent, in partbecause of the limited understanding of the processes involved in the development of epilepsy. It is generallyaccepted that up to 50% of all epileptic patients become epileptic as a result of a triggering initial injury such asstatus epilepticus, stroke or traumatic brain injury. This initial triggering injury has been postulated to activate acascade of events leading to further seizures, increased brain damage and self-propagation. Calpains are afamily of soluble calcium-dependent proteases, which have been implicated in epilepsy, since they are activatedby seizures and participate in neuronal damage. Recent studies have also indicated that during earlyepileptogenesis, seizure occurrence, calpain activity and neuronal damage are correlated, and that treatmentwith a non-selective calpain inhibitor reduces the development of spontaneous recurrent seizures (SRS) in thepilocarpine model of epilepsy in rats. Our laboratory has demonstrated that calpain-1 and calpain-2, two of themajor calpain isoforms in the brain, have opposite functions in the brain. We have also found that calpain-2conditional knock-out mice with calpain-2 deletion in excitatory neurons from the forebrain show normal seizureactivity following injections of repeated low doses of kainic acid (KA) but exhibit no brain inflammation, degeneration and cognitive impairment in hippocampus-dependent learning 7 days after seizures. Similarprotective results were obtained when wild-type mice were treated daily and for seven days after seizures witha selective calpain-2 inhibitor. These results strongly support the hypothesis that calpain-2 might represent apotential therapeutic target to prevent various pathological consequences of seizures. This Phase I STTR isdirected at first determining whether a selective calpain-2 inhibitor, NA-184, might prevent the appearance ofSRSs or reduce their frequency in two mouse models of epilepsy, the repeated low doses of kainic acid (KA) orof pilocarpine models (Aim #1). In Aim # 2, we will test the effects of intranasal administration of NA-184 on KA-and pilocarpine-induced neuropathology, as intranasal delivery of a variety of anti-epileptic drugs is increasinglyused in the clinic. In Phase II of this STTR, we will further pursue the development of intranasal delivery of NA-184 as an anti-epileptic treatment. NeurAegis is a small biotech company focusing on the development ofselective calpain-2 inhibitors for the treatment of acute neuronal injury, including traumatic brain injury andrepeated concussions. This proposal is directed at expanding the potential applications of these calpain-2inhibitors by determining whether they could also be developed as potential therapeutic treatment for epilepsy.

Public Health Relevance Statement:
Narrative There are currently no drugs that provide neuroprotection after status epilepticus. While calpain has been proposed to participate in the development of epilepsy as well as other neurodegenerative disorders, there are no calpain inhibitors in the clinic. The present studies will test the hypothesis that a selective calpain-2 inhibitor could prevent the occurrence of spontaneous recurring seizures following a seizure episode in two mouse models of epilepsy, in addition to preventing several manifestations of neuropathology. These studies will provide critical information to support the clinical development of a selective calpain-2 inhibitor for the treatment of epilepsy.

Project Terms:

Phase II

Contract Number: 5R41NS130825-02
Start Date: 9/1/2023    Completed: 5/31/2025
Phase II year
2024
Phase II Amount
$217,329
Epilepsy is the most prevalent neurological diseases after migraines. Current antiepileptic drug treatments mainly attempt to reduce excitation or enhance inhibition in order to control seizures. Unfortunately, such therapeutics result in a number of undesirable side-effects, and demonstrate limited efficacy against drug- resistant cases of epilepsy. So far, no treatment has been developed as an anti-epileptogenic agent, in part because of the limited understanding of the processes involved in the development of epilepsy. It is generally accepted that up to 50% of all epileptic patients become epileptic as a result of a triggering initial injury such as status epilepticus, stroke or traumatic brain injury. This initial triggering injury has been postulated to activate a cascade of events leading to further seizures, increased brain damage and self-propagation. Calpains are a family of soluble calcium-dependent proteases, which have been implicated in epilepsy, since they are activated by seizures and participate in neuronal damage. Recent studies have also indicated that during early epileptogenesis, seizure occurrence, calpain activity and neuronal damage are correlated, and that treatment with a non-selective calpain inhibitor reduces the development of spontaneous recurrent seizures (SRS) in the pilocarpine model of epilepsy in rats. Our laboratory has demonstrated that calpain-1 and calpain-2, two of the major calpain isoforms in the brain, have opposite functions in the brain. We have also found that calpain-2 conditional knock-out mice with calpain-2 deletion in excitatory neurons from the forebrain show normal seizure activity following injections of repeated low doses of kainic acid (KA) but exhibit no brain inflammation, degeneration and cognitive impairment in hippocampus-dependent learning 7 days after seizures. Similar protective results were obtained when wild-type mice were treated daily and for seven days after seizures with a selective calpain-2 inhibitor. These results strongly support the hypothesis that calpain-2 might represent a potential therapeutic target to prevent various pathological consequences of seizures. This Phase I STTR is directed at first determining whether a selective calpain-2 inhibitor, NA-184, might prevent the appearance of SRSs or reduce their frequency in two mouse models of epilepsy, the repeated low doses of kainic acid (KA) or of pilocarpine models (Aim #1). In Aim # 2, we will test the effects of intranasal administration of NA-184 on KA- and pilocarpine-induced neuropathology, as intranasal delivery of a variety of anti-epileptic drugs is increasingly used in the clinic. In Phase II of this STTR, we will further pursue the development of intranasal delivery of NA- 184 as an anti-epileptic treatment. NeurAegis is a small biotech company focusing on the development of selective calpain-2 inhibitors for the treatment of acute neuronal injury, including traumatic brain injury and repeated concussions. This proposal is directed at expanding the potential applications of these calpain-2 inhibitors by determining whether they could also be developed as potential therapeutic treatment for epilepsy.

Public Health Relevance Statement:
Narrative There are currently no drugs that provide neuroprotection after status epilepticus. While calpain has been proposed to participate in the development of epilepsy as well as other neurodegenerative disorders, there are no calpain inhibitors in the clinic. The present studies will test the hypothesis that a selective calpain-2 inhibitor could prevent the occurrence of spontaneous recurring seizures following a seizure episode in two mouse models of epilepsy, in addition to preventing several manifestations of neuropathology. These studies will provide critical information to support the clinical development of a selective calpain-2 inhibitor for the treatment of epilepsy. Terms:
© Copyright 1983-2025  |  Innovation Development Institute, LLC   |  Swampscott, MA  |  All Rights Reserved.